Journal articles on the topic 'Application to cancer therapy'

To see the other types of publications on this topic, follow the link: Application to cancer therapy.

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Application to cancer therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

MBBS MD, Dr Asmita Jain. "Metformin in Cancer Prevention and Therapy: New Application of an Old Drug." Journal of Medical Science And clinical Research 05, no. 04 (April 14, 2017): 20333–37. http://dx.doi.org/10.18535/jmscr/v5i4.97.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Misra, Ranjita, Sarbari Acharya, and Sanjeeb K. Sahoo. "Cancer nanotechnology: application of nanotechnology in cancer therapy." Drug Discovery Today 15, no. 19-20 (October 2010): 842–50. http://dx.doi.org/10.1016/j.drudis.2010.08.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Setayesh-Mehr, Zahra, and Mahdiye Poorsargol. "Toxic proteins application in cancer therapy." Molecular Biology Reports 48, no. 4 (April 2021): 3827–40. http://dx.doi.org/10.1007/s11033-021-06363-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Akiyode, O., D. George, J. Boateng, and G. Getti. "Application of Biosurfactants in Cancer Therapy." Annals of Oncology 26 (March 2015): ii28. http://dx.doi.org/10.1093/annonc/mdv095.4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Koohi Moftakhari Esfahani, Maedeh Koohi Moftakhari, Seyed Ebrahim Alavi, Peter J. Cabot, Nazrul Islam, and Emad L. Izake. "Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy." Pharmaceutics 14, no. 8 (July 29, 2022): 1579. http://dx.doi.org/10.3390/pharmaceutics14081579.

Full text
Abstract:
This review focuses on the biomedical application of mesoporous silica nanoparticles (MSNs), mainly focusing on the therapeutic application of MSNs for cancer treatment and specifically on overcoming the challenges of currently available anthelmintics (e.g., low water solubility) as repurposed drugs for cancer treatment. MSNs, due to their promising features, such as tunable pore size and volume, ability to control the drug release, and ability to convert the crystalline state of drugs to an amorphous state, are appropriate carriers for drug delivery with the improved solubility of hydrophobic drugs. The biomedical applications of MSNs can be further improved by the development of MSN-based multimodal anticancer therapeutics (e.g., photosensitizer-, photothermal-, and chemotherapeutics-modified MSNs) and chemical modifications, such as poly ethyleneglycol (PEG)ylation. In this review, various applications of MSNs (photodynamic and sonodynamic therapies, chemotherapy, radiation therapy, gene therapy, immunotherapy) and, in particular, as the carrier of anthelmintics for cancer therapy have been discussed. Additionally, the issues related to the safety of these nanoparticles have been deeply discussed. According to the findings of this literature review, the applications of MSN nanosystems for cancer therapy are a promising approach to improving the efficacy of the diagnostic and chemotherapeutic agents. Moreover, the MSN systems seem to be an efficient strategy to further help to decrease treatment costs by reducing the drug dose.
APA, Harvard, Vancouver, ISO, and other styles
6

Ko, Jeong-Hyeon, Seok-Geun Lee, Woong Yang, Jae-Young Um, Gautam Sethi, Srishti Mishra, Muthu Shanmugam, and Kwang Ahn. "The Application of Embelin for Cancer Prevention and Therapy." Molecules 23, no. 3 (March 9, 2018): 621. http://dx.doi.org/10.3390/molecules23030621.

Full text
Abstract:
Embelin is a naturally-occurring benzoquinone compound that has been shown to possess many biological properties relevant to human cancer prevention and treatment, and increasing evidence indicates that embelin may modulate various characteristic hallmarks of tumor cells. This review summarizes the information related to the various oncogenic pathways that mediate embelin-induced cell death in multiple cancer cells. The mechanisms of the action of embelin are numerous, and most of them induce apoptotic cell death that may be intrinsic or extrinsic, and modulate the NF-κB, p53, PI3K/AKT, and STAT3 signaling pathways. Embelin also induces autophagy in cancer cells; however, these autophagic cell-death mechanisms of embelin have been less reported than the apoptotic ones. Recently, several autophagy-inducing agents have been used in the treatment of different human cancers, although they require further exploration before being transferred from the bench to the clinic. Therefore, embelin could be used as a potential agent for cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Jiawei, Yan Bao, and Yandan Yao. "Application of Bionanomaterials in Tumor Immune Microenvironment Therapy." Journal of Immunology Research 2021 (February 10, 2021): 1–10. http://dx.doi.org/10.1155/2021/6663035.

Full text
Abstract:
Targeted therapy for the cancer immune system has become a clinical reality with remarkable success. Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. However, the clinical utility of immunotherapy in cancer is limited by severe off-target toxicity, long processing time, limited efficacy, and extremely high cost. Bionanomaterials combined with these therapies address these issues by enhancing immune regulation, integrating the synergistic effects of different molecules, and, most importantly, targeting and manipulating immune cells within the tumor. In this review, we will summarize the most current researches on bionanomaterials for targeted regulation of tumor-associated macrophages, myeloid-derived suppressor cells, dendritic cells, T lymphocyte cells, and cancer-associated fibroblasts and summarize the prospects and challenges of cell-targeted therapy and clinical translational potential in a tumor immune microenvironment in cancer treatment.
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Sumei, Shunqin Long, and Wanyin Wu. "Application of Traditional Chinese Medicines as Personalized Therapy in Human Cancers." American Journal of Chinese Medicine 46, no. 05 (January 2018): 953–70. http://dx.doi.org/10.1142/s0192415x18500507.

Full text
Abstract:
Although lots of great achievements have been gained in the battle against cancer during the past decades, cancer is still the leading cause of death in the world including in developing countries such as China. Traditional Chinese medicine (TCM) is popular in Chinese and East Asian societies as well as some other Western countries and plays an active role in the modern healthcare system including patients with cancer, which may act as a potential effective strategy in treating human cancers. In this review, we aimed to introduce the mechanisms of TCM compound, as an option of individualized therapy, in treating cancer patients from the perspective of both Chinese and Western medicine. In the view of traditional Chinese medicine theory, individualized treatment for human cancers based on syndrome type benefits the cancer patients with personalized conditions. Balancing Qi, Xue, Yin and Yang, eliminating phlegm and removing dampness is how TCM compound functions on cancer patients. While in the view of Western medicine, inhibiting cancer cell growth and metastasis as well as improving immune status is how herbal compounds act on cancer patients. We also summarized the applications of TCM compound in human cancers, which will shed light on the clinical application of TCM compound on patients with cancer. TCM compound could be used as a complementary and alternative medicine (CAM) in human cancers. It could be applied in cancer patients with cancer-related fatigue (CRF). In addition, it is a good method for alleviating the side effects of both radiotherapy and chemotherapy. Therefore, TCM compound plays a critical role in treating patients with cancer, which has a promising strategy in the field of cancer management.
APA, Harvard, Vancouver, ISO, and other styles
9

Ivanovic, Vesna. "Transforming growth factor-β: Biology and application to cancer therapy." Archive of Oncology 17, no. 3-4 (2009): 61–64. http://dx.doi.org/10.2298/aoo0904061i.

Full text
Abstract:
Transforming growth factor-? (TGF-?), an extensively investigated cytokine, plays a very important role in promoting the spread of cancers in the body, and can play a direct role in facilitating metastasis. Consequently, TGF-? is currently explored as a prognostic candidate biomarker of tumor invasiveness and metastasis. Therefore, in clinical scenarios involving increased TGF-? activity, attempts to decrease or abrogate TGF-? signaling could be used as a therapy for advanced or metastatic disease. It follows that TGF-? signaling offers an attractive target for cancer therapy. Several anti-TGF-? approaches, such as TGF-? antibodies, antisense oligonucleotides and small molecules inhibitors of TGF-? type 1 receptor kinase, have shown great promise in the preclinical studies. These studies, coupled with progressing clinical trials indicate that inhibition of TGF-? signaling may be indeed a viable option to cancer therapy. This review summarizes the TGF-? biology, screening cancer patients for anti-TGF-? therapy, and several strategies targeted against TGF-? signaling for cancer therapy. The next several years promise to improve our understanding of approaching cancer therapy by further evaluation of TGF-? signaling inhibitors for clinical efficacy. The complexity of TGF-? biology guarantees that many surprises lie ahead.
APA, Harvard, Vancouver, ISO, and other styles
10

Sargazi, Saman, Ushna Laraib, Simge Er, Abbas Rahdar, Mohadeseh Hassanisaadi, Muhammad Nadeem Zafar, Ana M. Díez-Pascual, and Muhammad Bilal. "Application of Green Gold Nanoparticles in Cancer Therapy and Diagnosis." Nanomaterials 12, no. 7 (March 27, 2022): 1102. http://dx.doi.org/10.3390/nano12071102.

Full text
Abstract:
Nanoparticles are currently used for cancer theranostics in the clinical field. Among nanoparticles, gold nanoparticles (AuNPs) attract much attention due to their usability and high performance in imaging techniques. The wide availability of biological precursors used in plant-based synthesized AuNPs allows for the development of large-scale production in a greener manner. Conventional cancer therapies, such as surgery and chemotherapy, have significant limitations and frequently fail to produce satisfying results. AuNPs have a prolonged circulation time, allow easy modification with ligands detected via cancer cell surface receptors, and increase uptake through receptor-mediated endocytosis. To exploit these unique features, studies have been carried out on the use of AuNPs as contrast agents for X-ray-based imaging techniques (i.e., computed tomography). As nanocarriers, AuNPs synthesized by nontoxic and biocompatible plants to deliver therapeutic biomolecules could be a significant stride forward in the effective treatment of various cancers. Fluorescent-plant-based markers, including AuNPs, fabricated using Medicago sativa, Olax Scandens, H. ambavilla, and H. lanceolatum, have been used in detecting cancers. Moreover, green synthesized AuNPs using various extracts have been applied for the treatment of different types of solid tumors. However, the cytotoxicity of AuNPs primarily depends on their size, surface reactivity, and surface area. In this review, the benefits of plant-based materials in cancer therapy are firstly explained. Then, considering the valuable position of AuNPs in medicine, the application of AuNPs in cancer therapy and detection is highlighted with an emphasis on limitations faced by the application of such NPs in drug delivery platforms.
APA, Harvard, Vancouver, ISO, and other styles
11

Acheampong, Desmond O. "Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy." Protein & Peptide Letters 26, no. 7 (July 22, 2019): 479–93. http://dx.doi.org/10.2174/0929866526666190311163820.

Full text
Abstract:
Development of cancers mostly involves more than one signal pathways, because of the complicated nature of cancer cells. As such, the most effective treatment option is the one that stops the cancer cells in their tracks by targeting these signal pathways simultaneously. This explains why therapeutic monoclonal antibodies targeted at cancers exert utmost activity when two or more are used as combination therapy. This notwithstanding, studies elsewhere have proven that when bispecific antibody (bsAb) is engineered from two conventional monoclonal antibodies or their chains, it produces better activity than when used as combination therapy. This therefore presents bispecific antibody (bsAb) as the appropriate and best therapeutic agent for the treatment of such cancers. This review therefore discusses the various engineering formats for bispecific antibodies (bsAbs) and their applications.
APA, Harvard, Vancouver, ISO, and other styles
12

Pinkawa, Michael. "Spacer application for prostate cancer radiation therapy." Future Oncology 10, no. 5 (April 2014): 851–64. http://dx.doi.org/10.2217/fon.13.223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Vetvicka, Vaclav. "Syntetic Oligosacharides – Clinical Application in Cancer Therapy." Anti-Cancer Agents in Medicinal Chemistry 13, no. 5 (May 1, 2013): 720–24. http://dx.doi.org/10.2174/1871520611313050006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Furusawa, Yoshiya. "Application of Quantum Beam for Cancer Therapy." IEEJ Transactions on Electronics, Information and Systems 137, no. 3 (2017): 390–93. http://dx.doi.org/10.1541/ieejeiss.137.390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Enriquez-Navas, Pedro M., Jonathan W. Wojtkowiak, and Robert A. Gatenby. "Application of Evolutionary Principles to Cancer Therapy." Cancer Research 75, no. 22 (November 2, 2015): 4675–80. http://dx.doi.org/10.1158/0008-5472.can-15-1337.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Cianfrocca, Mary. "Application of epothilones in breast cancer therapy." Current Opinion in Oncology 20, no. 6 (November 2008): 634–38. http://dx.doi.org/10.1097/cco.0b013e32831270b0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Rivas, J., M. Bañobre-López, Y. Piñeiro-Redondo, B. Rivas, and M. A. López-Quintela. "Magnetic nanoparticles for application in cancer therapy." Journal of Magnetism and Magnetic Materials 324, no. 21 (October 2012): 3499–502. http://dx.doi.org/10.1016/j.jmmm.2012.02.075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

YUHAS, JOHN M., ROBERT L. GOODMAN, and ROBERT E. MOORE. "Potential Application of Perfluorochemicals in Cancer Therapy." International Anesthesiology Clinics 23, no. 1 (1985): 199–210. http://dx.doi.org/10.1097/00004311-198502310-00018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Sun, Qiuyang, Yu Han, Yuming Yang, Jesús M. de la Fuente, Daxiang Cui, and Xiaoqiang Wang. "Application of DNA nanostructures in cancer therapy." Applied Materials Today 21 (December 2020): 100861. http://dx.doi.org/10.1016/j.apmt.2020.100861.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Mulé, J. J., S. G. Marcus, J. C. Yang, J. S. Weber, and S. A. Rosenberg. "Clinical application of IL6 in cancer therapy." Research in Immunology 143, no. 7 (January 1992): 777–83. http://dx.doi.org/10.1016/0923-2494(92)80023-e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Liu, Dan. "Application of EGFR targeted therapy in cancer." Precision Medicine Research 1, no. 1 (2019): 2–8. http://dx.doi.org/10.53388/pmr201900002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Liu, Wenhan, Zejun Wang, Yao Luo, and Nan Chen. "Application of Nanocomposites in Cancer Immunotherapy." Nano LIFE 07, no. 03n04 (December 2017): 1750008. http://dx.doi.org/10.1142/s1793984417500088.

Full text
Abstract:
Despite the clinical advances in oncology, cancer is still the major cause of death worldwide. Recent research demonstrates that the immune system plays a critical role in preventing tumor occurrence and development. The focus on cancer treatment has been shifted from directly targeting the tumor cells to motivating the immune system to achieve this goal. However, the activity of immune system is often suppressed in cancer patients. To boost the anti-tumor immunity against cancers, various nanocomposites have been developed to enhance the efficacy of immunostimulatory agents. Here, we review current advances in nanomaterial-mediated immunotherapy for the treatment of cancer, with an emphasis on applications of nanocomposites as immunoadjuvants in cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
23

Riggio, Cristina, Eleonora Pagni, Vittoria Raffa, and Alfred Cuschieri. "Nano-Oncology: Clinical Application for Cancer Therapy and Future Perspectives." Journal of Nanomaterials 2011 (2011): 1–10. http://dx.doi.org/10.1155/2011/164506.

Full text
Abstract:
Nano-oncology, the application of Nanomedicine to cancer diagnosis and treatment, has the potential to transform clinical oncology by enhancing the efficacy of cancer chemotherapy for a wide spectrum of invasive cancers. It achieves this by enabling novel drug delivery systems which target the tumour site with several functional molecules, including tumour-specific ligands, antibodies, cytotoxic agents, and imaging probes simultaneously thereby improving tumour response rates in addition to significant reduction of the systemic toxicity associated with current chemotherapy regimens. For this reason, nano-oncology is attracting considerable scientific interest and a growing investment by the global pharmaceutical industry. Several therapeutic nano-carriers have been approved for clinical use and others are undergoing phase II and III clinical trials. This paper describes the current approved formulations, such as liposomes and polymeric nanoparticles, and discusses the overall present status of nano-oncology as an emerging branch of nanomedicine and its future perspectives in cancer and therapy.
APA, Harvard, Vancouver, ISO, and other styles
24

Vodyashkin, Andrey A., Marko George Halim Rizk, Parfait Kezimana, Anatoly A. Kirichuk, and Yaroslav M. Stanishevskiy. "Application of Gold Nanoparticle-Based Materials in Cancer Therapy and Diagnostics." ChemEngineering 5, no. 4 (October 16, 2021): 69. http://dx.doi.org/10.3390/chemengineering5040069.

Full text
Abstract:
Several metal nanoparticles have been developed for medical application. While all have their benefits, gold nanoparticles (AuNPs) are ideal in cancer therapy and diagnosis as they are chemically inert and minimally toxic. Several studies have shown the potential of AuNPs in the therapeutic field, as photosensitizing agents in sonochemical and photothermal therapy and as drug delivery, as well as in diagnostics and theranostics. Although there is a significant number of reviews on the application of AuNPs in cancer medicine, there is no comprehensive review on their application both in therapy and diagnostics. Therefore, considering the high number of studies on AuNPs’ applications, this review summarizes data on the application of AuNPs in cancer therapy and diagnostics. In addition, we looked at the influence of AuNPs’ shape and size on their biological properties. We also present the potential use of hybrid materials based on AuNPs in sonochemical and photothermal therapy and the possibility of their use in diagnostics. Despite their potential, the use of AuNPs and derivatives in cancer medicine still has some limitations. In this review, we provide an overview of the biological, physicochemical, and legal constraints on using AuNPs in cancer medicine.
APA, Harvard, Vancouver, ISO, and other styles
25

Pokrovsky, Vadim S., Olga E. Chepikova, Denis Zh Davydov, Andrey A. Zamyatnin Jr, Alexander N. Lukashev, and Elena V. Lukasheva. "Amino Acid Degrading Enzymes and their Application in Cancer Therapy." Current Medicinal Chemistry 26, no. 3 (March 26, 2019): 446–64. http://dx.doi.org/10.2174/0929867324666171006132729.

Full text
Abstract:
Background:Amino acids are essential components in various biochemical pathways. The deprivation of certain amino acids is an antimetabolite strategy for the treatment of amino acid-dependent cancers which exploits the compromised metabolism of malignant cells. Several studies have focused on the development and preclinical and clinical evaluation of amino acid degrading enzymes, namely L-asparaginase, L-methionine γ-lyase, L-arginine deiminase, L-lysine α-oxidase. Further research into cancer cell metabolism may therefore define possible targets for controlling tumor growth.Objective:The purpose of this review was to summarize recent progress in the relationship between amino acids metabolism and cancer therapy, with a particular focus on Lasparagine, L-methionine, L-arginine and L-lysine degrading enzymes and their formulations, which have been successfully used in the treatment of several types of cancer.Methods:We carried out a structured search among literature regarding to amino acid degrading enzymes. The main aspects of search were in vitro and in vivo studies, clinical trials concerning application of these enzymes in oncology.Results:Most published research are on the subject of L-asparaginase properties and it’s use for cancer treatment. L-arginine deiminase has shown promising results in a phase II trial in advanced melanoma and hepatocellular carcinoma. Other enzymes, in particular Lmethionine γ-lyase and L-lysine α-oxidase, were effective in vitro and in vivo.Conclusion:The findings of this review revealed that therapy based on amino acid depletion may have the potential application for cancer treatment but further clinical investigations are required to provide the efficacy and safety of these agents.
APA, Harvard, Vancouver, ISO, and other styles
26

Zhu, Liangxi, Jingzhou Zhao, Zhukang Guo, Yuan Liu, Hui Chen, Zhu Chen, and Nongyue He. "Applications of Aptamer-Bound Nanomaterials in Cancer Therapy." Biosensors 11, no. 9 (September 18, 2021): 344. http://dx.doi.org/10.3390/bios11090344.

Full text
Abstract:
Cancer is still a major disease that threatens human life. Although traditional cancer treatment methods are widely used, they still have many disadvantages. Aptamers, owing to their small size, low toxicity, good specificity, and excellent biocompatibility, have been widely applied in biomedical areas. Therefore, the combination of nanomaterials with aptamers offers a new method for cancer treatment. First, we briefly introduce the situation of cancer treatment and aptamers. Then, we discuss the application of aptamers in breast cancer treatment, lung cancer treatment, and other cancer treatment methods. Finally, perspectives on challenges and future applications of aptamers in cancer therapy are discussed.
APA, Harvard, Vancouver, ISO, and other styles
27

Siddique, Sarkar, and James C. L. Chow. "Application of Nanomaterials in Biomedical Imaging and Cancer Therapy." Nanomaterials 10, no. 9 (August 29, 2020): 1700. http://dx.doi.org/10.3390/nano10091700.

Full text
Abstract:
Nanomaterials, such as nanoparticles, nanorods, nanosphere, nanoshells, and nanostars, are very commonly used in biomedical imaging and cancer therapy. They make excellent drug carriers, imaging contrast agents, photothermal agents, photoacoustic agents, and radiation dose enhancers, among other applications. Recent advances in nanotechnology have led to the use of nanomaterials in many areas of functional imaging, cancer therapy, and synergistic combinational platforms. This review will systematically explore various applications of nanomaterials in biomedical imaging and cancer therapy. The medical imaging modalities include magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computerized tomography, optical imaging, ultrasound, and photoacoustic imaging. Various cancer therapeutic methods will also be included, including photothermal therapy, photodynamic therapy, chemotherapy, and immunotherapy. This review also covers theranostics, which use the same agent in diagnosis and therapy. This includes recent advances in multimodality imaging, image-guided therapy, and combination therapy. We found that the continuous advances of synthesis and design of novel nanomaterials will enhance the future development of medical imaging and cancer therapy. However, more resources should be available to examine side effects and cell toxicity when using nanomaterials in humans.
APA, Harvard, Vancouver, ISO, and other styles
28

Lopes, Susana M. M., Marta Pineiro, and Teresa M. V. D. Pinho e Melo. "Corroles and Hexaphyrins: Synthesis and Application in Cancer Photodynamic Therapy." Molecules 25, no. 15 (July 29, 2020): 3450. http://dx.doi.org/10.3390/molecules25153450.

Full text
Abstract:
Corroles and hexaphyrins are porphyrinoids with great potential for diverse applications. Like porphyrins, many of their applications are based on their unique capability to interact with light, i.e., based on their photophysical properties. Corroles have intense absorptions in the low-energy region of the uv-vis, while hexaphyrins have the capability to absorb light in the near-infrared (NIR) region, presenting photophysical features which are complementary to those of porphyrins. Despite the increasing interest in corroles and hexaphyrins in recent years, the full potential of both classes of compounds, regarding biological applications, has been hampered by their challenging synthesis. Herein, recent developments in the synthesis of corroles and hexaphyrins are reviewed, highlighting their potential application in photodynamic therapy.
APA, Harvard, Vancouver, ISO, and other styles
29

Sharma, Deepa, Kai Xuan Leong, and Gregory J. Czarnota. "Application of Ultrasound Combined with Microbubbles for Cancer Therapy." International Journal of Molecular Sciences 23, no. 8 (April 15, 2022): 4393. http://dx.doi.org/10.3390/ijms23084393.

Full text
Abstract:
At present, cancer is one of the leading causes of death worldwide. Treatment failure remains one of the prime hurdles in cancer treatment due to the metastatic nature of cancer. Techniques have been developed to hinder the growth of tumours or at least to stop the metastasis process. In recent years, ultrasound therapy combined with microbubbles has gained immense success in cancer treatment. Ultrasound-stimulated microbubbles (USMB) combined with other cancer treatments including radiation therapy, chemotherapy or immunotherapy has demonstrated potential improved outcomes in various in vitro and in vivo studies. Studies have shown that low dose radiation administered with USMB can have similar effects as high dose radiation therapy. In addition, the use of USMB in conjunction with radiotherapy or chemotherapy can minimize the toxicity of high dose radiation or chemotherapeutic drugs, respectively. In this review, we discuss the biophysical properties of USMB treatment and its applicability in cancer therapy. In particular, we highlight important preclinical and early clinical findings that demonstrate the antitumour effect combining USMB and other cancer treatment modalities (radiotherapy and chemotherapy). Our review mainly focuses on the tumour vascular effects mediated by USMB and these cancer therapies. We also discuss several current limitations, in addition to ongoing and future efforts for applying USMB in cancer treatment.
APA, Harvard, Vancouver, ISO, and other styles
30

Wang, Zhouyao. "Applications of Polymers for Drug Delivery, Cancer Therapy and Antibacterial." Highlights in Science, Engineering and Technology 11 (August 23, 2022): 100–106. http://dx.doi.org/10.54097/hset.v11i.1271.

Full text
Abstract:
The mortality rate of cancer is gradually increasing every year. The application of polymers in biomedicine is one of the key research directions today. A number of researchers have found that polymers have great potential in chemotherapy, yet there is a research gap regarding the toxicity of the drugs to patients. Therefore, this research will introduce the application of a diverse of different polymer materials in biomedicine. Specifically, this research will mainly demonstrate the application of functional polymer materials in the following aspects, including drug delivery, anti-cancer, and antibacterial. On this basis, this study will also look forward to some development trends of polymer materials in the future application of biomedicine. This research suggestion is to find a way to combine the good biodegradability of thermos responsive polymers with the manipulability of magneto responsive carriers to achieve more desirable polymer applications.
APA, Harvard, Vancouver, ISO, and other styles
31

Dayani, Mohamad Ali. "A review on application of nanoparticles for cancer therapy." Immunopathologia Persa 5, no. 2 (July 14, 2019): e17-e17. http://dx.doi.org/10.15171/ipp.2019.17.

Full text
Abstract:
In recent years, scientific societies had warmly embraced nanotechnology as an emerging field in cancer therapy. Nanotechnology has had a profound influence on almost every aspect of the twenty-first century’s diurnal life. During the past years, nanomaterials have been successfully applied in different biomedical fields; especially in cancer therapy. While cancer is one of the deadliest disorders worldwide, there is a need to develop novel anticancer approaches. In this review, we explained various kinds of nanoparticles such as liposome-based and polymeric nanoparticles and dendrimers along with their applications in cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
32

Negahdary, Masoud, Ali Moradi, and Hossein Heli. "Application of electrochemical aptasensors in detection of cancer biomarkers." Biomedical Research and Therapy 6, no. 7 (July 28, 2019): 3315–24. http://dx.doi.org/10.15419/bmrat.v6i7.558.

Full text
Abstract:
Today, the late diagnosis of cancers is a big challenge, and using novel diagnostic techniques will provide essential, faster and more accurate treatments. Unfortunately, existing common and traditional diagnostic methods have not been helpful completely and most cancers are diagnosed too late. Recently, researchers have found new diagnostic methods against cancers by aptasensors; these sensory systems can detect involved biomarkers in various cancers so that the research in this field is continued strictly. Aptasensors can detect cancer markers in small quantities and high selectivity; moreover, other advantages of cancer aptasensors such as optimized time and cost saving can be considered. In addition, the aptasensors have been used in the diagnosis of the effective and related factors in cancer therapy follow-up. Here, the most researches about cancer aptasensors and other involved markers were collected, reviewed and described.
APA, Harvard, Vancouver, ISO, and other styles
33

Yasui, Wataru, and Eiichi Tahara. "Gene therapy: application to disease." Journal of Cancer Research and Clinical Oncology 124, no. 5 (May 19, 1998): 285–87. http://dx.doi.org/10.1007/s004320050169.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Xiao, Dexuan, and Ronghui Zhou. "Advances in the Application of Liposomal Nanosystems in Anticancer Therapy." Current Stem Cell Research & Therapy 16, no. 1 (December 1, 2021): 14–22. http://dx.doi.org/10.2174/1574888x15666200423093906.

Full text
Abstract:
Cancer is the disease with the highest mortality rate, which poses a great threat to people’s lives. Cancer caused approximately 3.4 million death worldwide annually. Surgery, chemotherapy and radiotherapy are the main therapeutic methods in clinical practice. However, surgery is only suitable for patients with early-stage cancers, and chemotherapy as well as radiotherapy have various side effects, both of which limit the application of available therapeutic methods. In 1965, liposome was firstly developed to form new drug delivery systems given the unique properties of nanoparticles, such as enhanced permeability and retention effect. During the last 5 decades, liposome has been widely used for the purpose of anticancer drug delivery, and several advances have been made regarding liposomal technology, including long-circulating liposomes, active targeting liposomes and triggered release liposomes, while problems exist all along. This review introduced the advances as well as the problems during the development of liposomal nanosystems for cancer therapy in recent years.
APA, Harvard, Vancouver, ISO, and other styles
35

Wang, X., L. Yang, Z. Chen, and D. M. Shin. "Application of Nanotechnology in Cancer Therapy and Imaging." CA: A Cancer Journal for Clinicians 58, no. 2 (January 28, 2008): 97–110. http://dx.doi.org/10.3322/ca.2007.0003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Saito, Hajime, Kazutaka Mitobe, and Yoshihiro Minamiya. "Medical application of magnetic materials for cancer therapy." Drug Delivery System 29, no. 4 (2014): 304–14. http://dx.doi.org/10.2745/dds.29.304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Tani, C., K. Kimura, A. Nakajima, K. Kato, H. Eiraku, K. Sajima, and T. Majima. "Clinical Application of Laser Therapy for Rectal Cancer." JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE 8, no. 3 (1987): 129–30. http://dx.doi.org/10.2530/jslsm1980.8.3_129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Luo, Shuang, Yujiao Wang, Yongyu Tao, Shuo Li, Zirui Wang, Wei He, Hangxing Wang, Nan Wang, Jianwei Xu, and Hailiang Song. "Application in Gene Editing in Ovarian Cancer Therapy." Cancer Investigation 40, no. 4 (November 11, 2021): 387–99. http://dx.doi.org/10.1080/07357907.2021.1998521.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Tylińska, Beata, and Benita Wiatrak. "Bioactive Olivacine Derivatives—Potential Application in Cancer Therapy." Biology 10, no. 6 (June 21, 2021): 564. http://dx.doi.org/10.3390/biology10060564.

Full text
Abstract:
Olivacine and its derivatives are characterized by multidirectional biological activity. Noteworthy is their antiproliferative effect related to various mechanisms, such as inhibition of growth factors, enzymes, kinases and others. The activity of these compounds was tested on cell lines of various tumors. In most publications, the most active olivacine derivatives exceeded the effects of doxorubicin (a commonly used anticancer drug), so in the future, they may become the main new anticancer drugs. In this publication, we present the groups of the most active olivacine derivatives obtained. In this work, the in vitro and in vivo activity of olivacine and its most active derivatives are presented. We describe olivacine derivatives that have been in clinical trials. We conducted a structure–activity relationship (SAR) analysis that may be used to obtain new olivacine derivatives with better properties than the available anticancer drugs.
APA, Harvard, Vancouver, ISO, and other styles
40

Terasaki, Paul I., Kiyoyasu Fukushima, Masaki Hirota, Hiroyuki Togashi, Hideo Mugishima, Yuichi Iwaki, Naofumi Suyama, et al. "Clinical application of monoclonal antibody for cancer therapy." Ensho 5, no. 2 (1985): 181–86. http://dx.doi.org/10.2492/jsir1981.5.181.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Tan, Fischer, L. "Application of RNAi to cancer research and therapy." Frontiers in Bioscience 10, no. 1-3 (2005): 1946. http://dx.doi.org/10.2741/1670.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Oonk, M. H. M., and A. G. J. van der Zee. "Application of sentinel nodes in gynaecological cancer therapy." European Journal of Cancer Supplements 11, no. 2 (September 2013): 287–88. http://dx.doi.org/10.1016/j.ejcsup.2013.07.054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Banerjee, S. M., A. J. MacRobert, C. A. Mosse, B. Periera, S. G. Bown, and M. R. S. Keshtgar. "Photodynamic therapy: Inception to application in breast cancer." Breast 31 (February 2017): 105–13. http://dx.doi.org/10.1016/j.breast.2016.09.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Nuccitelli, Richard. "Application of Pulsed Electric Fields to Cancer Therapy." Bioelectricity 1, no. 1 (March 2019): 30–34. http://dx.doi.org/10.1089/bioe.2018.0001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Knudsen, Helle, and Peter E. Nielsen. "Application of peptide nucleic acid in cancer therapy." Anti-Cancer Drugs 8, no. 2 (February 1997): 113–18. http://dx.doi.org/10.1097/00001813-199702000-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Andorsky, David J., and John M. Timmerman. "Interleukin-21: biology and application to cancer therapy." Expert Opinion on Biological Therapy 8, no. 9 (August 11, 2008): 1295–307. http://dx.doi.org/10.1517/14712598.8.9.1295.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Sumanasuriya, S., MB Lambros, and JS de Bono. "Application of Liquid Biopsies in Cancer Targeted Therapy." Clinical Pharmacology & Therapeutics 102, no. 5 (July 29, 2017): 745–47. http://dx.doi.org/10.1002/cpt.764.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Vingerhoeds, M. H., H. J. Haisma, M. van Muijen, R. B. J. van de Rijt, D. J. A. Crommelin, and G. Storm. "A new application for liposomes in cancer therapy." FEBS Letters 336, no. 3 (December 28, 1993): 485–90. http://dx.doi.org/10.1016/0014-5793(93)80861-n.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Zajakina, Anna, Karina Spunde, and Kenneth Lundstrom. "Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy." Current Pharmaceutical Design 23, no. 32 (December 21, 2017): 4906–32. http://dx.doi.org/10.2174/1381612823666170622094715.

Full text
Abstract:
Background: The lack of specific and efficient cancer therapies has influenced the development of novel approaches, such as immunotherapy, which from its original application of immunogenic protein delivery has developed into the use of more sophisticated recombinant gene delivery methods to achieve better safety and efficacy profiles. This approach involves viral and non-viral delivery systems. Methods: Expression vectors have been engineered for alphaviruses, including Semliki Forest virus, Sindbis virus and Venezuelan equine encephalitis virus. For immunotherapeutic applications, recombinant particles, RNA replicons and layered DNA vectors that express tumor-associated antigens (TAAs) and cytokines have been studied in animal models and in a few clinical trials. Results: Immunization studies with TAAs and cytokines have elicited strong antibody responses and vaccination has provided protection against challenges with tumor cells in mouse models. Furthermore, the combination of TAAs and cytokines, antibodies and growth factors and the co-administration of chemotherapeutics and bacteriabased adjuvants have enhanced immunogenicity. Intratumoral and systemic delivery of recombinant alphavirus particles has demonstrated significant tumor regression and prolonged survival rates in rodent tumor models. Conclusion: Alphavirus-based immunotherapy represents a rapid and efficient method for prophylactic and therapeutic applications in animal models.
APA, Harvard, Vancouver, ISO, and other styles
50

Boopathi, Ettickan, and Chellappagounder Thangavel. "Dark Side of Cancer Therapy: Cancer Treatment-Induced Cardiopulmonary Inflammation, Fibrosis, and Immune Modulation." International Journal of Molecular Sciences 22, no. 18 (September 19, 2021): 10126. http://dx.doi.org/10.3390/ijms221810126.

Full text
Abstract:
Advancements in cancer therapy increased the cancer free survival rates and reduced the malignant related deaths. Therapeutic options for patients with thoracic cancers include surgical intervention and the application of chemotherapy with ionizing radiation. Despite these advances, cancer therapy-related cardiopulmonary dysfunction (CTRCPD) is one of the most undesirable side effects of cancer therapy and leads to limitations to cancer treatment. Chemoradiation therapy or immunotherapy promote acute and chronic cardiopulmonary damage by inducing reactive oxygen species, DNA damage, inflammation, fibrosis, deregulation of cellular immunity, cardiopulmonary failure, and non-malignant related deaths among cancer-free patients who received cancer therapy. CTRCPD is a complex entity with multiple factors involved in this pathogenesis. Although the mechanisms of cancer therapy-induced toxicities are multifactorial, damage to the cardiac and pulmonary tissue as well as subsequent fibrosis and organ failure seem to be the underlying events. The available biomarkers and treatment options are not sufficient and efficient to detect cancer therapy-induced early asymptomatic cell fate cardiopulmonary toxicity. Therefore, application of cutting-edge multi-omics technology, such us whole-exome sequencing, DNA methylation, whole-genome sequencing, metabolomics, protein mass spectrometry and single cell transcriptomics, and 10 X spatial genomics, are warranted to identify early and late toxicity, inflammation-induced carcinogenesis response biomarkers, and cancer relapse response biomarkers. In this review, we summarize the current state of knowledge on cancer therapy-induced cardiopulmonary complications and our current understanding of the pathological and molecular consequences of cancer therapy-induced cardiopulmonary fibrosis, inflammation, immune suppression, and tumor recurrence, and possible treatment options for cancer therapy-induced cardiopulmonary toxicity.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography